An FDA panel said that data on Merck’s chronic cough drug gefapixant does not provide enough evidence to prove its clinical benefit for patients, Reuters’ Christy Santhosh and Khushi Mandowara report. The FDA advisers voted 12-1 against the data, which showed a small reduction in cough frequency, the authors note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRK:
- Cantor biotech/biopharma analysts hold analyst/industry conference call
- 5 Top Growth Stocks to Buy Now, According to Analysts – November 2023
- FDA approves Merck’s Keytruda plus chemotherapy as first-line treatment
- Pembrolizumab with chemo approved for HER2-negative gastric or GEJ adenocarcinoma
- Natera enters oncology research agreement with Merck